161 related articles for article (PubMed ID: 9393300)
1. Soluble urinary CD14 after intravesical bacille Calmette-Guérin immunotherapy for carcinoma in situ.
Jackson AM; Lien E; Alexandroff AB; Prescott S; Espevik T; James K; Selby PJ; Sundan A
Br J Urol; 1997 Nov; 80(5):766-71. PubMed ID: 9393300
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
[TBL] [Abstract][Full Text] [Related]
3. Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis.
Jackson AM; Ivshina AV; Senko O; Kuznetsova A; Sundan A; O'Donnell MA; Clinton S; Alexandroff AB; Selby PJ; James K; Kuznetsov VA
J Urol; 1998 Mar; 159(3):1054-63. PubMed ID: 9474231
[TBL] [Abstract][Full Text] [Related]
4. Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder.
Merz VW; Marth D; Kraft R; Ackermann DK; Zingg EJ; Studer UE
Br J Urol; 1995 Feb; 75(2):180-4. PubMed ID: 7850322
[TBL] [Abstract][Full Text] [Related]
5. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy.
Jackson AM; Alexandroff AB; Kelly RW; Skibinska A; Esuvaranathan K; Prescott S; Chisholm GD; James K
Clin Exp Immunol; 1995 Mar; 99(3):369-75. PubMed ID: 7882559
[TBL] [Abstract][Full Text] [Related]
6. Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder.
Nunez-Nateras R; Castle EP; Protheroe CA; Stanton ML; Ocal TI; Ferrigni EN; Ochkur SI; Jacobsen EA; Hou YX; Andrews PE; Colby TV; Lee NA; Lee JJ
Urol Oncol; 2014 Jan; 32(1):45.e23-30. PubMed ID: 24055426
[TBL] [Abstract][Full Text] [Related]
7. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.
De Boer EC; De Jong WH; Van Der Meijden AP; Steerenberg PA; Witjes JA; Vegt PD; Debruyne FM; Ruitenberg EJ
Cancer Immunol Immunother; 1991; 33(6):411-6. PubMed ID: 1878894
[TBL] [Abstract][Full Text] [Related]
8. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis.
de Boer EC; de Jong WH; van der Meijden AP; Steerenberg PA; Witjes F; Vegt PD; Debruyne FM; Ruitenberg EJ
Urol Res; 1991; 19(1):45-50. PubMed ID: 2028562
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms.
Prescott S; Jackson AM; Hawkyard SJ; Alexandroff AB; James K
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S91-3. PubMed ID: 11010831
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress of red blood cells during Bacillus Calmette-Guerin intravesical instillations.
Mitropoulos D; Deliconstantinos G; Zervas A; Giannopoulos A; Kyriakou G; Dimopoulos C
In Vivo; 2000; 14(6):721-4. PubMed ID: 11204488
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.
Lamm DL; Blumenstein BA; Crawford ED; Montie JE; Scardino P; Grossman HB; Stanisic TH; Smith JA; Sullivan J; Sarosdy MF
N Engl J Med; 1991 Oct; 325(17):1205-9. PubMed ID: 1922207
[TBL] [Abstract][Full Text] [Related]
12. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
13. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.
De Boer EC; De Jong WH; Steerenberg PA; Aarden LA; Tetteroo E; De Groot ER; Van der Meijden AP; Vegt PD; Debruyne FM; Ruitenberg EJ
Cancer Immunol Immunother; 1992; 34(5):306-12. PubMed ID: 1540977
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of local immune response after intravesical bacille Calmette-Guérin treatment for superficial bladder cancer.
Patard JJ; Muscatelli-Groux B; Saint F; Popov Z; Maille P; Abbou C; Chopin D
Br J Urol; 1996 Nov; 78(5):709-14. PubMed ID: 8976765
[TBL] [Abstract][Full Text] [Related]
15. Intravesical instillation of bacille Calmette-Guérin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter.
Irie A; Iwamura M; Kadowaki K; Ohkawa A; Uchida T; Baba S
Urology; 2002 Jan; 59(1):53-7. PubMed ID: 11796281
[TBL] [Abstract][Full Text] [Related]
16. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation.
Takayama H; Nishimura K; Tsujimura A; Nakai Y; Nakayama M; Aozasa K; Okuyama A; Nonomura N
J Urol; 2009 Apr; 181(4):1894-900. PubMed ID: 19237175
[TBL] [Abstract][Full Text] [Related]
17. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
18. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
[TBL] [Abstract][Full Text] [Related]
19. Evolution of carcinoma in situ under intravesical Romanian Bacille Calmette-Guérin therapy.
Geavlete P; Taşcă C
Rom J Morphol Embryol; 1991; 37(1-2):69-74. PubMed ID: 1801982
[TBL] [Abstract][Full Text] [Related]
20. Intravesical Evans Bacille Calmette-Guérin in the treatment of carcinoma in situ.
Cumming JA; Hargreave TB; Webb JN; McIntyre MA; Chisholm GD
Br J Urol; 1989 Mar; 63(3):259-63. PubMed ID: 2702423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
